Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 9Phase 1/2 4Phase 4 3Phase 3 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 84Unknown 40Terminated 20Recruiting 17Not yet recruiting 10Withdrawn 5Active not recruiting 4Suspended 3

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Pneumonia 1Lung Diseases, Interstitial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

icotinib 1Prednisone 1Erlotinib Hydrochloride 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Suspended × Thoracic × Clear all
NCT04036721 2023-02-23

PROS-CONS

National Institute for Tuberculosis and Lung Diseases, Poland

Phase 4 Suspended
85 enrolled
Thoracic

Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial

NCT01320501 2016-05-13

REALME

National Guard Health Affairs

Phase 4 Suspended
100 enrolled
Thoracic

Lung Neoplasms

NCT01720901 2015-05-22

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Betta Pharmaceuticals Co., Ltd.

Phase 4 Suspended
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡